2025 – Talk Bio

The 5 Largest Biopharma Layoffs of Q1 2025: An Overview of Industry Restructuring

2 weeks ago talkbio0Tagged 2025, Biopharma layoffs, Drug Industry, Galapagos layoffs, Gilead, Industry, losses, Merck, Myers, Novartis, Q1 2025, restructuring, Squibb Layoffs, trends qualifier

Biopharma layoffs 2025, Novartis layoffs, Galapagos layoffs, Bristol Myers Squibb layoffs, Merck cuts, Gilead workforce reduction, Q1 2025 job cuts, biotech restructuring, pharmaceutical industry job losses, industry trends.

FDA to Decide on Merck’s Subcutaneous Keytruda in September 2025

4 weeks ago talkbio0Tagged 2025, Cancer Therapeutic Procedure, Co., Decision, Merck & Co., PDUFA, September 23, Subcutaneous Keytruda, United States Food and Drug Administration

Subcutaneous Keytruda, FDA decision, September 23, 2025, Merck & Co., cancer treatment, PDUFA date

A closer look at pharmas top patent losses in 2025

1 month ago talkbio0Tagged 2023, 2025, Bayer, competition, Expiration, function, Impact food supplement, Indication of (contextual qualifier), Legal patent, Market, Patent Cliff, Regeneron, Sales - occupational activity

Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023

Six Payer Trends Shaping Market Access in 2025

1 month ago talkbio0Tagged 2025, Access, Artificial Intelligence, Enrollment, Market, payer, payers, Shapes, trends qualifier

Market, trends qualifier, Access, Enrollment, 2025, payer, Shapes, payers, Artificial Intelligence

Novo Nordisk Projects Slower Growth for 2025, Targets CagriSema Approval in 2026

3 months ago talkbio0Tagged 2025, CagriSema, Drug Industry, Growth, Nordisk, Obesity, regulatory approval, Sales - occupational activity, Wegovy

Novo Nordisk, 2025 outlook, CagriSema, obesity treatment, pharmaceutical industry, Wegovy, sales growth, regulatory approval

Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025

3 months ago talkbio0Tagged 2025, Braftovi, Cancer Therapeutic Procedure, Colorectal Carcinoma, Immunotherapy, Metastasis from malignant neoplasm of colon and/or rectum, Myers, Opdivo, Pfizer, squibb, Yervoy

Colorectal cancer, metastatic colorectal cancer, Bristol Myers Squibb, Pfizer, Opdivo, Yervoy, Braftovi, ASCO GI 2025, cancer treatment, immunotherapy.

Sionna and Odyssey Therapeutics Kick Off 2025 Biotech IPO Wave with SEC Filings

3 months ago talkbio0Tagged 2025, File (record), Health care facility, Industry, IPO, JPM, Market, Odyssey, Sionna

Sionna Therapeutics, Odyssey Therapeutics, IPO filings, biotech industry, JPM Healthcare Conference, 2025 IPO market

Charles River Laboratories Forecasts Revenue Decline in 2025 Amid CDMO Challenges

3 months ago talkbio0Tagged 2025, Biopharma, business career, CDMO, Charles, constraints, Drug Industry, IL31RA gene, revenue outlook, River Laboratories, spending, trends qualifier

Charles River Laboratories, CRL, 2025 revenue outlook, CDMO business challenges, biopharma spending constraints, pharmaceutical industry trends

BridgeBio Pharma Reports Strong Commercial Progress and Pipeline Updates for 2025

3 months ago talkbio0Tagged 2025, Attruby, BridgeBio Pharma, Clinical Trials, commercial, FORTIFY, Hereditary Diseases, milestones, Phase 3, Propel, status - In progress

BridgeBio Pharma, Attruby, commercial progress, pipeline updates, 2025 milestones, rare genetic diseases, Phase 3 clinical trials, FORTIFY, CALIBRATE, PROPEL 3.

Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline

3 months ago talkbio0Tagged 2025, competition, cost-cutting measures, COVID19 (disease), decline, Market, Moderna, Vaccination, Vaccines

Moderna, 2025 revenue forecast, cost-cutting measures, vaccine sales decline, COVID-19 vaccine market competition, falling vaccination rates.